Read more about the article 23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million

23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million

23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company that has used…

Continue Reading23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million

End of content

No more pages to load